|
1
|
Kanada KN, Merin MR, Munden A and
Friedlander SF: A prospective study of cutaneous fifindings in
newborns in the United States: Correlation with race, ethnicity,
and gestational status using updated classifification and
nomenclature. J Pediatr. 161:240–245. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kilcline C and Frieden IJ: Infantile
hemangiomas: How common are they? A systematic review of the
medical literature. Pediatr Dermatol. 25:168–173. 2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Couto RA, Maclellan RA, Zurakowski D and
Greene AK: Infantile hemangioma: Clinical assessment of the
involuting phase and implications for management. Plast Reconstr
Surg. 130:619–624. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nguyen HP, Pickrell BB and Wright TS:
Beta-blockers as therapy for infantile hemangiomas. Semin Plast
Surg. 28:87–90. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Priya C, Varshini C and Biswakumar B: Case
report: A rare case of infantile hemangioma, treated in a private
clinic as out patient. Prim Health Care. 9(321)2019.
|
|
6
|
Wu Y, Li H, Xie J, Wang F, Cao D and Lou
Y: miR-139-5p affects cell proliferation, migration and
adipogenesis by targeting insulin-like growth factor 1 receptor in
hemangioma stem cells. Int J Mol Med. 45:569–577. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jin W, Chen L, Gao F, Yang M, Liu Y and
Wang B: Down-regulation of miR-556-3p inhibits hemangioma cell
proliferation and promotes apoptosis by targeting VEGFC. Cell Mol
Biol (Noisy-le-grand). 66:204–207. 2020.PubMed/NCBI
|
|
8
|
Lim LH and Pervaiz S: Annexin 1: The new
face of an old molecule. FASEB J. 21:968–975. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Biaoxue R, Xiguang C and Shuanying Y:
Annexin A1 in malignant tumors: Current opinions and controversies.
Int J Biol Markers. 29:e8–e20. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rubinstein MR, Baik JE, Lagana SM, Han RP,
Raab WJ, Sahoo D, Dalerba P, Wang TC and Han YW: Fusobacterium
nucleatum promotes colorectal cancer by inducing Wnt/β-catenin
modulator Annexin A1. EMBO Rep. 20(e47638)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Boudhraa Z, Rondepierre F, Ouchchane L,
Kintossou R, Trzeciakiewicz A, Franck F, Kanitakis J, Labeille B,
Joubert-Zakeyh J, Bouchon B, et al: Annexin A1 in primary tumors
promotes melanoma dissemination. Clin Exp Metastasis. 31:749–760.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pessolano E, Belvedere R, Bizzarro V,
Franco P, Marco I, Porta A, Tosco A, Parente L, Perretti M and
Petrella A: Annexin A1 may induce pancreatic cancer progression as
a key player of extracellular vesicles effects as evidenced in the
in vitro MIA PaCa-2 model system. Int J Mol Sci.
19(3878)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lin Y, Lin G, Fang W, Zhu H and Chu K:
Increased expression of annexin A1 predicts poor prognosis in human
hepatocellular carcinoma and enhances cell malignant phenotype. Med
Oncol. 31(327)2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Paweletz CP, Ornstein DK, Roth MJ, Bichsel
VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH,
Herring J, et al: Loss of annexin 1 correlates with early onset of
tumorigenesis in esophageal and prostate carcinoma. Cancer Res.
60:6293–6297. 2000.PubMed/NCBI
|
|
15
|
Zhu DW, Yang X, Yang CZ, Ma J, Liu Y, Yan
M, Wang LZ, Li J, Zhang CP, Zhang ZY and Zhong LP: Annexin A1
down-regulation in oral squamous cell carcinoma correlates to
pathological differentiation grade. Oral Oncol. 49:542–550.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ge Y, Li S, Hu XY, Tong HL, Li SF and Yan
YQ: TCEA3 promotes differentiation of C2C12 cells via an Annexin
A1-mediated transforming growth factor-β signaling pathway. J Cell
Physiol. 234:10554–10565. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vishwanatha JK, Salazar E and
Gopalakrishnan VK: Absence of annexin I expression in B-cell
non-Hodgkin's lymphomas and cell lines. BMC Cancer.
4(8)2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
de Jong S, Itinteang T, Withers AH, Davis
PF and Tan ST: Does hypoxia play a role in infantile hemangioma?
Arch Dermatol Res. 308:219–227. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Adams JM, Difazio LT, Rolandelli RH, Luján
JJ, Haskó G, Csóka B, Selmeczy Z and Németh ZH: HIF-1: A key
mediator in hypoxia. Acta Physiol Hung. 96:19–28. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Marchuk DA: Pathogenesis of hemangioma. J
Clin Invest. 107:665–666. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Aydin Köker S, Kömüroğlu AU, Köksoy AY,
Şiraz ÜG, Tekin E and Köker A: Evaluation of GLUT1, IGF-2, VEGF,
FGF 1, and angiopoietin 2 in infantile hemangioma. Arch Pediatr.
28:296–300. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yin RR, Hao D and Chen P: Expression and
correlation of MMP-9, VEGF, and p16 in infantile hemangioma. Eur
Rev Med Pharmacol Sci. 22:4806–4811. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Thaivalappil S, Bauman N, Saieg A, Movius
E, Brown KJ and Preciado D: Propranolol-mediated attenuation of
MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head
Neck Surg. 139:1026–1031. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Şen HS, Yalçın B, Canpınar H, Ocak S and
Akyüz C: Serum levels of VEGF and bFGF in infantile hemangiomas
treated with propranolol. Turk J Pediatr. 62:979–985.
2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Park M, Jung HL, Shim YJ, Kim HS, Yoon HS,
Park SK, Cheuh HW, Lee MJ, Lee JM, Park ES, et al: Serum cytokine
profiles in infants with infantile hemangiomas on oral propranolol
treatment: VEGF and bFGF, potential biomarkers predicting clinical
outcomes. Pediatr Res. 88:749–755. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rotter A, Lima XT and Oliveira ZNP:
Evaluation of plasma and urinary levels of vascular endothelial
growth factor and matrix metalloproteinase-9 in patients with
infantile hemangioma. Int J Dermatol. 60:1263–1269. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lacerda JZ, Drewes CC, Mimura KKO, Zanon
CF, Ansari T, Gil CD, Greco KV, Farsky SHP and Oliani SM: Annexin
A12-26 treatment improves skin heterologous
transplantation by modulating inflammation and angiogenesis
processes. Front Pharmacol. 9(1015)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yi M and Schnitzer JE: Impaired tumor
growth, metastasis, angiogenesis and wound healing in annexin
A1-null mice. Proc Natl Acad Sci USA. 106:17886–17891.
2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ramakrishnan S, Anand V and Roy S:
Vascular endothelial growth factor signaling in hypoxia and
inflammation. J Neuroimmune Pharmacol. 9:142–160. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang X, Tang G and Sun H: Effect of
hypoxia on the proliferation and expressions of hypoxia-inducible
factor-1α, vascular endothelial growth factor and matrix
metalloproteinase-9 in keratinocytes obtained from oral lichen
planus lesions. Zhonghua Kou Qiang Yi Xue Za Zhi. 50:89–94.
2015.PubMed/NCBI(In Chinese).
|
|
31
|
Liao SH, Zhao XY, Han YH, Zhang J, Wang
LS, Xia L, Zhao KW, Zheng Y, Guo M and Chen GQ: Proteomics-based
identification of two novel direct targets of hypoxia-inducible
factor-1 and their potential roles in migration/invasion of cancer
cells. Proteomics. 9:3901–3912. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yang F, Cai J, Zhan H, Situ J, Li W, Mao Y
and Luo Y: Suppression of TRPM7 inhibited hypoxia-induced migration
and invasion of androgen-independent prostate cancer cells by
enhancing RACK1-mediated degradation of HIF-1α. Oxid Med Cell
Longev. 2020(6724810)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lee CC, Chen SC, Tsai SC, Wang BW, Liu YC,
Lee HM and Shyu KG: Hyperbaric oxygen induces VEGF expression
through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein
endothelial cells. J Biomed Sci. 13:143–156. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Catar R, Moll G, Hosp I, Simon M, Luecht
C, Zhao H, Wu D, Chen L, Kamhieh-Milz J, Korybalska K, et al:
Transcriptional regulation of thrombin-induced endothelial VEGF
induction and proangiogenic response. Cells. 10(910)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Poeter M, Radke S, Koese M, Hessner F,
Hegemann A, Musiol A, Gerke V, Grewal T and Rescher U: Disruption
of the annexin A1/S100A11 complex increases the migration and
clonogenic growth by dysregulating epithelial growth factor (EGF)
signaling. Biochim Biophys Acta. 1833:1700–1711. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pin AL, Houle F, Fournier P, Guillonneau
M, Paquet ÉR, Simard MJ, Royal I and Huot J: Annexin-1-mediated
endothelial cell migration and angiogenesis are regulated by
vascular endothelial growth factor (VEGF)-induced inhibition of
miR-196a expression. J Biol Chem. 287:30541–30551. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wei L, Li L, Liu L, Yu R, Li X and Luo Z:
Knockdown of Annexin-A1 Inhibits growth, migration and invasion of
glioma cells by suppressing the PI3K/Akt signaling pathway. ASN
Neuro. 13(17590914211001218)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Minet E, Arnould T, Michel G, Roland I,
Mottet D, Raes M, Remacle J and Michiels C: ERK activation upon
hypoxia: Involvement in HIF-1 activation. FEBS Lett. 468:53–58.
2000.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Liu L, Ning X, Han S, Zhang H, Sun L, Shi
Y, Sun S, Guo C, Yin F, Qiao T, et al: Hypoxia induced HIF-1
accumulation and VEGF expression in gastric epithelial mucosa
cells: Involvement of ERK1/2 and PI3K/Akt. Mol Biol (Mosk).
42:459–469. 2008.PubMed/NCBI(In Russian).
|
